Expression and significance of Wnt signaling components and their target genes in breast carcinoma

He,Yanjiao; Liu,Zhaoxia; Qiao,Chao; Xu,Miaosheng; Yu,Jin; Li,Guang

doi:10.3892/mmr.2013.1774

Expression and significance of Wnt signaling components and their target genes in breast carcinoma

Authors:
- Yanjiao He
- Zhaoxia Liu
- Chao Qiao
- Miaosheng Xu
- Jin Yu
- Guang Li
View Affiliations

Affiliations: Department of Pathology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China
Published online on: November 4, 2013 https://doi.org/10.3892/mmr.2013.1774
Pages: 137-143

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the expression of β-catenin, axin, cyclin D1 and c-myc, and their correlation with various clinicopathological factors of breast carcinoma. Using immunohistochemistry, the expression of axin, β-catenin, cyclin D1 and c-myc proteins was detected in 168 breast carcinomas and 40 normal breast tissue samples, as well as in 72 breast intraductal proliferative lesions. Correlations among the expression of these proteins with the clinicopathological factors of breast carcinomas were subsequently analyzed. Gene mutations of β-catenin (exon 3) in 44 cases of breast carcinoma were analyzed using polymerase chain reaction (PCR) followed by direct sequencing. In normal tissue, the epithelial cells demonstrated a marked membranous expression of β-catenin protein at cell-cell boundaries and positive axin expression; cyclin D1 and c-myc expression, however, were negative. The abnormal rate of β-catenin expression and the overexpression of cyclin D1 and c-myc were higher in breast carcinomas compared with breast cystic hyperplasia tissues. Positive axin expression levels were lower in breast carcinomas compared with breast intraductal proliferative lesions and normal breast tissues. Axin expression correlated inversely with tumor size, histological grade, clinical tumor, node, metastasis (TNM) stage and lymph node metastasis. The abnormal expression of β-catenin and the overexpression of cyclin D1 were correlated, and the overexpression of c-myc was correlated with tumor size, histological grade, clinical TNM stage and lymph node metastasis. The abnormal expression of β-catenin was correlated with the overexpression of cyclin D1, but not with the overexpression of c-myc. Lower levels of axin expression were correlated with higher levels of nuclear β-catenin expression. Mutations in the β-catenin gene were not detected in 44 cases of breast carcinoma. The abnormal expression of β-catenin may be key in the carcinogenesis and progression of human breast carcinoma by upregulating the expression of cyclin D1. The abnormal expression of β-catenin, the reduced expression of axin, and the overexpression of cyclin D1 and c-myc may be useful markers for determining metastasis, providing a prognosis for human breast carcinoma and for guiding treatment.

View Figures

View References

1	Paul S and Dey A: Wnt signaling and cancer development: therapeutic implication. Neoplasma. 55:165–176. 2008.PubMed/NCBI
2	Prosperi JR and Goss KH: A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer. Curr Drug Targets. 11:1074–1088. 2010. View Article : Google Scholar : PubMed/NCBI
3	Miller JR: The Wnts. Genome Biol. 3:1–15. 2002.
4	Polakis P: Wnt signaling and cancer. Genes Dev. 14:1837–1851. 2000.
5	Lustig B and Behrens J: The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol. 129:199–221. 2003.PubMed/NCBI
6	Van Aken E, De Wever O, Correia da Rocha AS and Mareel M: Defective E-cadherin/catenin complexes in human cancer. Virchows Arch. 439:725–751. 2001.PubMed/NCBI
7	Luo W and Lin SC: Axin: a master scaffold for multiple signaling pathways. Neurosignals. 13:99–113. 2004. View Article : Google Scholar : PubMed/NCBI
8	Böcker W: WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics. Verh Dtsch Ges Pathol. 86:116–119. 2002.(In German).
9	Maruyama K, Ochiai A, Akimoto S, et al: Cytoplasmic beta-catenin as a predictor of hematogenous metastasis in human colorectal cancer. Oncology. 59:302–309. 2000. View Article : Google Scholar : PubMed/NCBI
10	Nakajima M, Fukuchi M, Miyazaki T, et al: Reduced expression of Axin correlates with tumour progression of oesophageal squamous cell carcinoma. Br J Cancer. 88:1734–1739. 2003. View Article : Google Scholar : PubMed/NCBI
11	Bankfalvi A, Terpe HJ, Breukelmann D, et al: Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. Histopathology. 34:25–34. 1999. View Article : Google Scholar : PubMed/NCBI
12	Lin SY, Xia W, Wang JC, et al: Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA. 97:4262–4266. 2000. View Article : Google Scholar : PubMed/NCBI
13	Lim SC and Lee MS: Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer. Oncol Rep. 9:915–928. 2002.PubMed/NCBI
14	Dolled-Filhart M, McCabe A, Giltnane J, et al: Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res. 66:5487–5494. 2006. View Article : Google Scholar : PubMed/NCBI
15	López-Knowles E, Zardawi SJ, McNeil CM, et al: Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev. 19:301–309. 2010.PubMed/NCBI
16	Chung GG, Zerkowski MP, Ocal IT, et al: beta-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer. 100:2084–2092. 2004. View Article : Google Scholar : PubMed/NCBI
17	Wang Z, Ren Y, He JJ, et al: Relationship between ectopic expression of Wnt/beta-catenin signaling pathway and Her-2 overexpression in human breast carcinoma. J Xi’an Jiaotong Univ (Med Sci). 30:587–591. 2009.
18	Kikuchi A: Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci. 94:225–229. 2003. View Article : Google Scholar : PubMed/NCBI
19	He YJ, Jia XS, Qing SKZ, et al: The study on p53 and beta-catenin gene mutations in NK/T cell lymphoma. Chin J Clin Oncol. 31:1385–1388. 2004.
20	Zhuang SM, Wiseman RW and Söderkvist P: Frequent mutations of the Trp53, Hras1 and beta-catenin (Catnb) genes in 1,3-butadiene-induced mammary adenocarcinomas in B6C3F1 mice. Oncogene. 21:5643–5648. 2002. View Article : Google Scholar : PubMed/NCBI
21	Howe LR and Brown AM: Wnt signaling and breast cancer. Cancer Biol Ther. 3:36–41. 2004. View Article : Google Scholar
22	Ozaki S, Ikeda S, Ishizaki Y, et al: Alterations and correlations of the components in the Wnt signaling pathway and its target genes in breast cancer. Oncol Rep. 14:1437–1443. 2005.PubMed/NCBI
23	Kizildag S, Zengel B, Vardar E, et al: beta-catenin gene mutation in invasive ductal breast cancer. J BUON. 13:533–536. 2008.PubMed/NCBI
24	Abraham SC, Rcynolds C, Lee JH, et al: Fibromatosis of the breast and mutations involving the APC/beta-catenin pathway. Hum Pathol. 33:39–46. 2002. View Article : Google Scholar : PubMed/NCBI
25	Zeng L, Fagotto F, Zhang T, et al: The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell. 90:181–192. 1997. View Article : Google Scholar : PubMed/NCBI
26	Xu HT, Wang L, Lin D, et al: Abnormal beta-catenin and reduced axin expression are associated with poor differentiation and progression in non-small cell lung cancer. Am J Clin Pathol. 125:534–541. 2006. View Article : Google Scholar : PubMed/NCBI
27	Ishizaki Y, Ikeda S, Fujimori M, et al: Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas. Int J Oncol. 24:1077–1083. 2004.PubMed/NCBI
28	Jin LH, Shao QJ, Luo W, et al: Detection of point mutations of the Axin1 gene in colorectal cancers. Int J Cancer. 107:696–699. 2003. View Article : Google Scholar : PubMed/NCBI
29	Cong F and Varmus H: Nuclear-cytoplasmic shuttling of Axin regulates subcellular localization of beta-catenin. Proc Natl Acad Sci USA. 101:2882–2887. 2004. View Article : Google Scholar : PubMed/NCBI
30	Cliffe A, Hamada F and Bienz M: A role of Dishevelled in relocating Axin to the plasma membrane during wingless signaling. Curr Biol. 13:960–966. 2003. View Article : Google Scholar
31	Roh MS, Hong SH, Jeong JS, et al: Gene expression profiling of breast cancer with emphasis of beta-catenin regulation. J Korean Med Sci. 19:275–282. 2004. View Article : Google Scholar : PubMed/NCBI